Healthcare -
Medical - Instruments & Supplies - NASDAQ - IL
$ 6.62
1.38 %
$ 3.76 M
Market Cap
None
P/E
1. INTRINSIC VALUE
2. FUNDAMENTAL
ANALYSIS
Price Chart GCTK
FINANCIALS
Balance Sheet
GlucoTrack, Inc.
| Current Assets | 5.77 M |
| Cash & Short-Term Investments | 5.62 M |
| Receivables | 0 |
| Other Current Assets | 151 K |
| Non-Current Assets | 164 K |
| Long-Term Investments | 0 |
| PP&E | 154 K |
| Other Non-Current Assets | 10 K |
| Current Liabilities | 1.28 M |
| Accounts Payable | 992 K |
| Short-Term Debt | 31 K |
| Other Current Liabilities | 252 K |
| Non-Current Liabilities | 17.7 M |
| Long-Term Debt | 236 K |
| Other Non-Current Liabilities | 17.4 M |
EFFICIENCY
Earnings Waterfall
GlucoTrack, Inc.
| Revenue | 0 |
| Cost Of Revenue | 36 K |
| Gross Profit | 0 |
| Operating Expenses | 0 |
| Operating Income | -14.5 M |
| Other Expenses | 8.05 M |
| Net Income | -22.6 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
GlucoTrack, Inc.
| Net Income | -22.6 M |
| Depreciation & Amortization | 36 K |
| Capital Expenditures | -104 K |
| Stock-Based Compensation | 173 K |
| Change in Working Capital | 67 K |
| Others | 9.64 M |
| Free Cash Flow | -12.6 M |
Wall Street Analysts Price Targets
GlucoTrack, Inc.
GCTK has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
GCTK does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
GlucoTrack, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
24 M USD 5
9-12 MONTHS
7. News
Why Is This Nano-Cap Glucotrack Stock Trading Higher On Wednesday?
Glucotrack Inc. GCTK stock traded higher on Wednesday, with a session volume of 15.91 million compared to the average of 81.7K, according to data from Benzinga Pro.
benzinga.com
- 2 weeks ago
Glucotrack and OneTwo Analytics Present Positive Final Results of First-In-Human Study for Continuous Blood Glucose Monitor at American Diabetes Association's 85th Scientific Sessions
RUTHERFORD, N.J. and STOCKHOLM, June 25, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced results from its completed first-in-human clinical study presented at the American Diabetes Association's (ADA) 85th Scientific Sessions, which took place June 20-23, 2025, in Chicago.
globenewswire.com
- 2 weeks ago
Glucotrack Announces Reverse Stock Split Shareholder Approved Action Meets NASDAQ Panel Hearing Listing Requirements
1-for-60 reverse stock split to become effective as of the opening of trading on June 16, 2025 Rutherford, NJ, June 12, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will effect a 1-for-60 reverse stock split (the “Reverse Stock Split”) of its issued and outstanding common stock par value $0.001 per share (the “Common Stock”), effective with the opening of trading on Monday, June 16, 2025. Glucotrack's Common Stock will continue to trade on the Nasdaq Capital Market (“Nasdaq”) under the symbol “GCTK”.
globenewswire.com
- 3 weeks ago
Glucotrack to Showcase Long-Term Continuous Blood Glucose Monitor at American Diabetes Association's 85th Scientific Sessions
Glucotrack to present on next-generation continuous blood glucose monitoring technology in Innovation Hub Poster presentation to highlight insights on safety and performance data from direct blood glucose measurement technology RUTHERFORD, N.J., June 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced it will present safety and performance data from its first-in-human trial of its implantable continuous blood glucose monitoring (CBGM) system.
globenewswire.com
- 1 month ago
Glucotrack Strengthens Board of Directors with Election of Victoria E. Carr-Brendel, PhD
Experienced medical device executive with deep expertise in implantable technologies joins Glucotrack as Company advances development of long-term implantable blood glucose monitoring technology Experienced medical device executive with deep expertise in implantable technologies joins Glucotrack as Company advances development of long-term implantable blood glucose monitoring technology
globenewswire.com
- 1 month ago
Glucotrack Establishes Patient Advisory Board to Inform Diabetes Technology Development
Patients get a seat at the table in development of long-term implantable continuous blood glucose monitoring technology Patients get a seat at the table in development of long-term implantable continuous blood glucose monitoring technology
globenewswire.com
- 1 month ago
Glucotrack Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
On track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025
globenewswire.com
- 1 month ago
Glucotrack Announces Ethical Approval for Long-Term Clinical Study of Continuous Blood Glucose Monitor
Long-term clinical evaluation represents key advancement following successful first-in-human study Long-term clinical evaluation represents key advancement following successful first-in-human study
globenewswire.com
- 1 month ago
Glucotrack to Participate in FORGETDIABETES, a Prominent European Research Initiative to Develop a Bionic Pancreas
RUTHERFORD, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will participate in the FORGETDIABETES bionic pancreas initiative that will develop a long-term, automated insulin delivery system that will enable optimal glucose control without patient intervention.
globenewswire.com
- 2 months ago
Glucotrack and OneTwo Analytics to Collaborate for Clinical Study Analysis on Its Continuous Blood Glucose Monitor
Next Generation AI-Driven Analytics to Unlock Key Insights from the Ongoing Continuous Blood Glucose Monitoring Clinical Study Data Next Generation AI-Driven Analytics to Unlock Key Insights from the Ongoing Continuous Blood Glucose Monitoring Clinical Study Data
globenewswire.com
- 3 months ago
Glucotrack Reports Full Year 2024 Financial Results and Recent Corporate Highlights
Transformational 2024: successfully advanced from preclinical to clinical stage company Strengthened leadership team to drive growth and advance clinical development Investigational Device Exemption (IDE) approval for continuous blood glucose monitoring (CBGM) technology from FDA expected in Q4 2025 Rutherford, NJ, March 31, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today reported financial results and recent corporate highlights for the fourth quarter and full year ended December 31, 2024. “2024 was transformative for Glucotrack as we advanced the development of our CBGM technology and successfully transitioned from a preclinical to a clinical stage company.
globenewswire.com
- 3 months ago
Glucotrack to Present First-In-Human Study Results for Continuous Blood Glucose Monitor at the 2025 International Conference on Advanced Technologies & Treatment for Diabetes
Safety and performance data from direct blood glucose measurement technology to be featured at international diabetes technology conference Safety and performance data from direct blood glucose measurement technology to be featured at international diabetes technology conference
globenewswire.com
- 3 months ago
8. Profile
Summary
GlucoTrack, Inc. GCTK
COUNTRY
IL
INDUSTRY
Medical - Instruments & Supplies
MARKET CAP
$ 3.76 M
Dividend Yield
0.00%
Description
GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally. It develops GlucoTrack glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.
Contact
8 Ariel Sharon Street, Or Yehuda, 7760049
https://www.glucotrack.com
IPO
Date
April 25, 2013
Employees
11
Officers
Mr. David Malka BA
Co-Founder
Mr. Peter C. Wulff
Chief Financial Officer, Treasurer & Secretary
Ms. Drinda Benjamin
Vice President of Marketing
Mr. Avner Gal MBA, MSc.EE
Co-Founder, Chairman Emeritus, Consultant and Member of Scientific & Clinical Advisory Board
Mr. Vincent Wong
Vice President of Operations
Mr. Paul V. Goode Ph.D.
Chief Executive Officer, President & Director
Mr. Mark Tapsak Ph.D.
Chief Scientific Officer